| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/25/2004 | CA2498308A1 Parathyroid hormone-like polypeptides |
| 03/25/2004 | CA2498274A1 Compositions and methods for the diagnosis of immune related diseases using pro7 |
| 03/25/2004 | CA2498044A1 Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
| 03/25/2004 | CA2498004A1 Compositions and methods for the diagnosis and treatment of tumor |
| 03/25/2004 | CA2498000A1 Use of tumor-associated kinase (task) 110 antagonists for treating pancreatic cancers |
| 03/25/2004 | CA2497890A1 A mechanism for hiv-1 entry into host cells and peptides inhibiting this mechanism |
| 03/25/2004 | CA2497661A1 Compositions and methods for the diagnosis of immune related diseases using pro71061 |
| 03/25/2004 | CA2497356A1 Nucleic acid sequences encoding novel point mutations on mglur2 and mglur3 |
| 03/25/2004 | CA2497337A1 Novel composition and methods for the treatment of psoriasis |
| 03/25/2004 | CA2497334A1 Novel compositions and methods for the treatment of immune related diseases |
| 03/25/2004 | CA2497226A1 Pharmaceutical compositions and medical treatments comprising notch ligand proteins |
| 03/25/2004 | CA2497132A1 Method of diagnosing ovarian endometriosis |
| 03/25/2004 | CA2496319A1 Mammalian megakaryocyte progenitor cell |
| 03/25/2004 | CA2496318A1 Hydroxyalkyl starch derivatives |
| 03/25/2004 | CA2496317A1 Method of producing hydroxyalkyl starch derivatives |
| 03/25/2004 | CA2496213A1 Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
| 03/25/2004 | CA2495242A1 Hasylated polypeptides, especially hasylated erythropoietin |
| 03/25/2004 | CA2494274A1 Method and composition for regulating the activity of regulatory t cells |
| 03/25/2004 | CA2494216A1 Use of dendritic cells (dcs) expressing interleukin 12 (il-12) |
| 03/24/2004 | EP1400596A1 Androgen receptor complex-associated protein |
| 03/24/2004 | EP1400592A1 Streptococcus pneumoniae polynucleotides and sequences |
| 03/24/2004 | EP1400550A1 Branched polyalkylene glycols |
| 03/24/2004 | EP1400536A1 Method for making humanized antibodies |
| 03/24/2004 | EP1400533A1 HASylated polypeptides, especially HASylated erythropoietin |
| 03/24/2004 | EP1400530A1 Suppression of immune response via inhibition of cathepsin S |
| 03/24/2004 | EP1400252A1 Methods and compositions for healing and repair of articular cartilage |
| 03/24/2004 | EP1400245A1 Boronic acid salts useful in parenteral formulations for selective thrombin inhibition |
| 03/24/2004 | EP1400241A1 Fused cyclic compounds and medicinal use thereof |
| 03/24/2004 | EP1399744A2 Epf receptor assays, compounds and therapeutic compositions |
| 03/24/2004 | EP1399740A2 Type 1 diabetes diagnostics and therapeutics |
| 03/24/2004 | EP1399739A2 Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy |
| 03/24/2004 | EP1399587A2 Nucleic acids of the human abca5, abca6, abca9, and abca10 genes, vectors containing such nucleic acids and uses thereof |
| 03/24/2004 | EP1399586A2 Method to identify genes associated with chronic myelogenous leukemia |
| 03/24/2004 | EP1399584A2 Cancer-linked genes as targets for chemotherapy |
| 03/24/2004 | EP1399578A2 Adsls as modifiers of the p53 pathway and methods of use |
| 03/24/2004 | EP1399570A2 Peptides for use as translocation factors |
| 03/24/2004 | EP1399565A2 Mitogenic oxygenase regulators |
| 03/24/2004 | EP1399564A2 Drug metabolizing enzymes |
| 03/24/2004 | EP1399563A2 Moraxella (branhamella) catarrhalis antigens |
| 03/24/2004 | EP1399558A2 Vanilloid receptor-related nucleic acids and polypeptides |
| 03/24/2004 | EP1399557A2 Brain expressed gene and protein associated with bipolar disorder |
| 03/24/2004 | EP1399556A2 Antigenic epitopes of factor viii, inhibitors directed against said epitopes and use thereof |
| 03/24/2004 | EP1399553A2 Polynucleotides encoding cellular transporters and methods of use therof |
| 03/24/2004 | EP1399552A2 G-protein coupled receptor proteins (gpcr) and nucleic acids encoding same |
| 03/24/2004 | EP1399549A1 Anticomplement polypeptide from salivary glands of the tick ixodes ricinus |
| 03/24/2004 | EP1399548A2 Conjugate of a transport protein and a protein for modulation of notch signalling |
| 03/24/2004 | EP1399544A2 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof |
| 03/24/2004 | EP1399537A2 Therapeutic polypeptides, nucleic acids encoding same and methods of use |
| 03/24/2004 | EP1399499A1 Agent for the prevention and treatment of sexually transmitted diseases-i |
| 03/24/2004 | EP1399479A2 Cation conducting gaba a receptors and their use |
| 03/24/2004 | EP1399478A2 Cancer-testis antigens |
| 03/24/2004 | EP1399476A1 Use of soluble cytokeratine-1-fragments in diagnostics and therapy |
| 03/24/2004 | EP1399475A2 Mutants of igf binding proteins and methods of production of antagonists thereof |
| 03/24/2004 | EP1399474A2 Secreted proteins and their use |
| 03/24/2004 | EP1399472A2 Soluble heterodimeric cytokine receptor |
| 03/24/2004 | EP1399471A2 Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders |
| 03/24/2004 | EP1399470A2 Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents |
| 03/24/2004 | EP1399469A2 Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis |
| 03/24/2004 | EP1399468A1 2-((n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl)-amino)-alkylboronic acid derivatives |
| 03/24/2004 | EP1399467A2 Peptide deformylase activated prodrugs |
| 03/24/2004 | EP1399466A2 Compounds and methods for the modulation of cd154 |
| 03/24/2004 | EP1399462A1 Combined approach to treatment of cancer using a c-myc antisense oligomer |
| 03/24/2004 | EP1399460A2 Breast cancer-associated genes and uses thereof |
| 03/24/2004 | EP1399426A2 Compounds, compositions and methods for modulating beta-amyloid production |
| 03/24/2004 | EP1399221A1 Compositions comprising oestrone-3-o-sulphamate and trail (tnf-related apoptosis inducing ligand) |
| 03/24/2004 | EP1399215A2 Tissue-specific endothelial membrane proteins |
| 03/24/2004 | EP1399206A2 Hydrophobic dopamine agonists administered to the dermis |
| 03/24/2004 | EP1399205A2 Enhanced systemic absorption of intradermally delivered substances |
| 03/24/2004 | EP1399184A2 Uses of mammalian genes and related reagents |
| 03/24/2004 | EP1399183A2 Chimeric alphavirus replicon particles |
| 03/24/2004 | EP1399180A2 Sulfated ccr5 peptides for hiv-1 infection |
| 03/24/2004 | EP1399179A2 Pharmaceutical compositions which inhibit proliferation of pituitary adenomas and method of use thereof |
| 03/24/2004 | EP1399178A2 Method of treating metabolic disorders using neuronatin polypeptides |
| 03/24/2004 | EP1399177A1 Bmp binding proteins for use in bone or cartilage regeneration |
| 03/24/2004 | EP1399176A1 Substantially pure glycopeptide antibiotics ac-98-1; ac-98-2; ac-98-3; ac-98-4 and ac-98-5 |
| 03/24/2004 | EP1399175A2 Therapeutic use of rank antagonists |
| 03/24/2004 | EP1399174A2 Nucleic acid and corresponding protein entitled 121p1f1 useful in treatment and detection of cancer |
| 03/24/2004 | EP1399157A1 Combination comprising a p-gp inhibitor and an anti-epileptic drug |
| 03/24/2004 | EP1399133A2 Sustained-release composition comprising lactic acid-glycolic acid copolymer and process for producing the same |
| 03/24/2004 | EP1399132A1 Production of hard, dense particles |
| 03/24/2004 | EP1399113A1 Cosmetic or dermatological composition comprising n-acylaminoamide derivatives |
| 03/24/2004 | EP1399108A2 Preparation of a therapeutic composition |
| 03/24/2004 | EP1399023A2 Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins |
| 03/24/2004 | EP1292606A4 Positively-charged peptide nucleic acid analogs with improved properties |
| 03/24/2004 | EP1231934B1 Methods of inhibiting atrophy or promoting hypertrophy |
| 03/24/2004 | EP1194534A4 Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses |
| 03/24/2004 | EP1162991A4 Arginine-rich anti-vascular endothelial growth factor peptides that inhibit growth and metastasis of human tumor cells by blocking angiogenesis |
| 03/24/2004 | EP1150693B1 Immunogenic compositions for use as vaccines |
| 03/24/2004 | EP1124847B1 Lhrh analogues for the treatment of osteoporosis |
| 03/24/2004 | EP1121456A4 In vitro and in vivo models for screening compounds to prevent glucocorticoid-induced bone destruction |
| 03/24/2004 | EP1115415B1 Use of gnrh analogues in the treatment of schizophrenia |
| 03/24/2004 | EP0957930B1 Substance p treatment for immunostimulation |
| 03/24/2004 | EP0946592B1 Immuno-reactive peptide ctl epitopes of human cytomegalovirus |
| 03/24/2004 | EP0869970B1 Endothelial cell proliferation inhibitor and its use |
| 03/24/2004 | EP0869812B1 C-c chemokines that inhibit retrovirus infection |
| 03/24/2004 | EP0850319B1 Method for modulating cell apoptosis |
| 03/24/2004 | EP0795015B1 Plasmids suitable for il-2 expression |
| 03/24/2004 | EP0784469B1 Compositions for the delivery of antigens |
| 03/24/2004 | EP0777494B1 Human chemokine polypeptides |
| 03/24/2004 | EP0758341B1 FACTOR Xa INHIBITORS |